MapLight Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, MapLight Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
MapLight Therapeutics: 5 sponsored US clinical trials, 4 recruiting.
MapLight Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Psychosis Associated With Alzheimer's Disease, with 1 trials.
Upper-quartile sponsor footprint
MapLight Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
NCT07038876
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
Therapeutic Areas
What is open in the MapLight Therapeutics pipeline
4 recruiting of 5 indexed (80% open).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Psychosis Associated With Alzheimer's Disease (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
MapLight Therapeutics: open-pipeline peers nationwide
Peers matched on 5 registered trials and 80% open enrollment, not the therapeutic-area sidebar.
MapLight Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 80% open enrollment (± trial volume)
- Alpha Tau Medical · 80% recruiting · 5 trials
- Buck Institute for Research on Aging · 80% recruiting · 5 trials
- IDEAYA Biosciences · 80% recruiting · 10 trials
- Mirador Therapeutics · 80% recruiting · 5 trials
Related
What to do with this MapLight Therapeutics page
5 registered trials is a research-attention snapshot, not an endorsement of MapLight Therapeutics or any single study.
- 4 of MapLight Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Psychosis Associated With Alzheimer's Disease is the condition MapLight Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Psychosis Associated With Alzheimer's Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
MapLight Therapeutics pipeline card: 5 registered trials from official public datasets.Report a data error.